Medium-chain triglyceride (MCT) oil and fatty liver disease are increasingly discussed topics, yet confusion persists about whether MCT oil can help or harm liver health. MCT oil is a dietary supplement derived from coconut or palm kernel oil, containing fatty acids that are metabolised differently from typical dietary fats. Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of UK adults and is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Whilst MCT oil's unique metabolism has sparked interest in its potential effects on liver fat, it is crucial to understand the evidence, safety considerations, and proven management strategies for fatty liver disease.

What Is MCT Oil and How Does It Work?

Medium-chain triglyceride (MCT) oil is a food supplement derived from coconut oil or palm kernel oil, containing fatty acids with chain lengths of 6 to 12 carbon atoms. Unlike long-chain triglycerides found in most dietary fats, MCTs with 8 and 10 carbon atoms (caprylic and capric acids) are absorbed more rapidly in the gastrointestinal tract and transported predominantly via the portal vein directly to the liver, bypassing the lymphatic system. Lauric acid (C12), whilst sometimes classified as an MCT, behaves metabolically more like a long-chain fatty acid and is partly absorbed via the lymphatic route.

The primary MCTs include caproic acid (C6), caprylic acid (C8), capric acid (C10), and lauric acid (C12). Once in the liver, C8 and C10 fatty acids undergo rapid beta-oxidation in the mitochondria largely without requiring carnitine transport, making them a quick energy source. C12 follows a more mixed metabolic pathway. This unique metabolism has generated interest in MCT oil's potential applications, including weight management and cognitive function support, though evidence remains investigational and MCT oil has no licensed medicinal indications in the UK.

In the context of liver health, MCT oil's metabolism differs from long-chain fatty acids. Because C8 and C10 are preferentially oxidised for energy rather than stored as fat, some researchers have hypothesised they might reduce hepatic lipid accumulation. However, there is no established evidence that MCT oil supplementation treats or prevents fatty liver disease. The liver processes MCTs differently, but this does not translate to proven therapeutic benefit for existing liver conditions.

MCT oil is available as a clear, flavourless liquid supplement and is increasingly found in functional foods, protein powders, and ketogenic diet products. Typical commercial preparations contain predominantly C8 and C10 fatty acids, as these are considered the most efficiently metabolised forms. MCT oil is regulated in the UK as a food supplement, not as a medicine licensed by the MHRA.

Understanding Fatty Liver Disease: Causes and Risk Factors

Non-alcoholic fatty liver disease (NAFLD) is characterised by excessive fat accumulation in hepatocytes (liver cells) in individuals who consume little or no alcohol. It represents a spectrum of conditions, from simple steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to fibrosis, cirrhosis, or hepatocellular carcinoma. (The terminology is evolving internationally, with some guidelines now using metabolic dysfunction-associated steatotic liver disease [MASLD], though NAFLD remains the term in current UK guidance.)

According to NICE guideline NG49, NAFLD affects approximately 20–30% of the UK population and is strongly associated with metabolic syndrome. Key risk factors include:

• Obesity and central adiposity – particularly visceral fat accumulation

• Type 2 diabetes mellitus – insulin resistance is a central pathophysiological mechanism

• Dyslipidaemia – elevated triglycerides and low HDL cholesterol

• Hypertension – part of the metabolic syndrome cluster

• Sedentary lifestyle – lack of physical activity contributes to metabolic dysfunction

The pathogenesis involves a 'multiple-hit' hypothesis, where insulin resistance leads to increased hepatic lipogenesis and reduced fatty acid oxidation, whilst oxidative stress, inflammatory cytokines, and gut-derived endotoxins contribute to hepatocellular injury and fibrosis.

Alcoholic fatty liver disease (AFLD) shares similar histological features but results from excessive alcohol consumption. For diagnostic purposes, NAFLD is typically considered when alcohol intake is below thresholds that would cause alcoholic liver disease (often cited as <14 units per week for women and <21 units per week for men in older literature, though current UK Chief Medical Officers' low-risk drinking guidance advises ≤14 units per week for both sexes). The distinction is clinically important as management strategies differ.

Other causes of hepatic steatosis include certain medications (corticosteroids, methotrexate, tamoxifen, amiodarone), viral hepatitis C, rapid weight loss, total parenteral nutrition, and conditions such as Wilson's disease, haemochromatosis, hypothyroidism, coeliac disease, polycystic ovary syndrome, and HIV-related lipodystrophy. Most cases of NAFLD are asymptomatic and discovered incidentally through abnormal liver function tests or imaging performed for other reasons.

Safe Use of MCT Oil: Dosage and Potential Side Effects

If considering MCT oil supplementation, understanding appropriate dosing and potential adverse effects is essential for patient safety. MCT oil has no MHRA-approved therapeutic indication for fatty liver disease and should not be considered a treatment for this condition. However, for those using it as a dietary supplement, evidence-based guidance can minimise risks.

Typical dosing recommendations suggest starting with small amounts (1 teaspoon or approximately 5 ml daily) and gradually increasing to 1–2 tablespoons (15–30 ml) daily, divided into 2–3 doses with meals. This gradual titration helps minimise gastrointestinal side effects. Some ketogenic diet protocols use higher doses (up to 50–70 ml daily), but these should only be undertaken with professional supervision.

Common adverse effects include:

• Gastrointestinal disturbances – diarrhoea, abdominal cramping, bloating, and nausea are the most frequently reported side effects, particularly with rapid dose escalation or high intake

• Increased bowel frequency – the osmotic effect of unabsorbed MCTs can cause loose stools

• Abdominal discomfort – some individuals experience stomach upset or indigestion

These effects are generally dose-dependent and resolve with dose reduction or discontinuation. Taking MCT oil with food may improve tolerability.

Important contraindications and precautions:

Individuals with decompensated cirrhosis or severe hepatic impairment should consult their hepatologist or GP before using MCT oil, as the liver metabolises these fats and additional metabolic burden may be inappropriate. Those with diabetes, particularly if using insulin or sulfonylureas, should monitor blood glucose, as evidence on MCT effects on insulin sensitivity is limited and individual responses may vary. Patients with fat malabsorption disorders (such as pancreatic insufficiency or short bowel syndrome) should seek medical advice. Pregnancy and breastfeeding: safety data are limited; consult your GP or midwife before use. Individuals with coconut or palm kernel allergies should avoid MCT oil derived from these sources.

MCT oil is energy-dense (approximately 8.3 kcal per gram, or about 115 kcal per tablespoon [15 ml]), so excessive consumption may contribute to weight gain, potentially worsening fatty liver disease. Choose reputable UK- or EU-compliant food supplements with clear labelling and, ideally, independent quality testing to ensure purity and avoid contaminants.

If you experience any suspected side effects from MCT oil or any supplement, you can report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Lifestyle Changes for Managing Fatty Liver Disease

Evidence-based lifestyle modification remains the cornerstone of NAFLD management, with robust data supporting its effectiveness in reducing hepatic steatosis and preventing disease progression. NICE guideline NG49 recommends a comprehensive approach addressing diet, physical activity, and metabolic risk factors.

Weight management is paramount. Studies demonstrate that 5–10% body weight reduction significantly decreases liver fat content, whilst weight loss exceeding 10% can improve or resolve NASH and reduce fibrosis. This should be achieved gradually (0.5–1 kg weekly) through sustainable dietary changes rather than crash dieting, which may paradoxically worsen liver inflammation. The NHS offers structured weight-management programmes and the NHS Diabetes Prevention Programme for those at risk.

Dietary recommendations include:

• Mediterranean-style diet – emphasising vegetables, fruits, whole grains, legumes, nuts, olive oil, and lean proteins (particularly fish)

• Reduced refined carbohydrates and added sugars – limiting sugar-sweetened beverages, processed foods, and high-glycaemic-index carbohydrates

• Moderate protein intake – adequate protein supports satiety and preserves lean muscle mass during weight loss

• Limited saturated fat – reducing red meat, full-fat dairy, and processed meats

• Avoiding excessive fructose – particularly from soft drinks and fruit juices

Physical activity provides benefits independent of weight loss. The UK Chief Medical Officers' physical activity guidelines recommend 150 minutes of moderate-intensity aerobic exercise weekly (such as brisk walking, cycling, or swimming) plus muscle-strengthening activities on at least two days per week. Even without weight loss, regular exercise improves insulin sensitivity, reduces liver fat, and decreases cardiovascular risk.

Managing comorbidities is essential. Optimising glycaemic control in diabetes, treating dyslipidaemia, and controlling hypertension all contribute to improved outcomes. Patients should avoid hepatotoxic substances, particularly alcohol. Current UK Chief Medical Officers' low-risk drinking guidance advises ≤14 units per week for both men and women (1 unit = 8 g ethanol), spread over at least three days with several alcohol-free days. For individuals with advanced fibrosis or cirrhosis, complete abstinence is recommended. Discuss your individual situation with your GP.

Smoking cessation is strongly encouraged, as smoking is associated with accelerated fibrosis progression. The NHS Stop Smoking Service provides evidence-based support including behavioural counselling and pharmacotherapy.

Vaccination against hepatitis A and B is recommended for individuals with chronic liver disease, in line with UK Health Security Agency (UKHSA) guidance.

When to Seek Medical Advice About Fatty Liver

Fatty liver disease is often asymptomatic in early stages, making awareness of when to seek medical evaluation crucial for timely intervention and prevention of progression to advanced liver disease.

You should contact your GP if you:

• Have abnormal liver function tests detected during routine blood work or health screening

• Experience persistent fatigue that interferes with daily activities, particularly if accompanied by other symptoms

• Notice unexplained weight loss or loss of appetite

• Develop abdominal discomfort or pain in the right upper quadrant (below the right ribcage)

• Have risk factors for NAFLD (obesity, type 2 diabetes, metabolic syndrome) and have never had liver assessment

• Are taking medications known to affect the liver and develop new symptoms

Seek urgent medical attention (contact 111 or attend A&E) if you develop:

• Jaundice – yellowing of the skin or whites of the eyes

• Dark urine or pale stools

• Severe abdominal pain or swelling

• Confusion or altered mental state (potential hepatic encephalopathy)

• Vomiting blood or passing black, tarry stools (signs of gastrointestinal bleeding)

• Easy bruising or bleeding that does not stop

These symptoms may indicate advanced liver disease or acute liver injury requiring immediate assessment.

Initial assessment typically involves liver function tests (ALT, AST, ALP, bilirubin, albumin), metabolic screening (glucose, HbA1c, lipid profile), and viral hepatitis serology, in line with British Society of Gastroenterology (BSG) guidance on abnormal liver blood tests. Ultrasound scanning is the first-line imaging modality for detecting hepatic steatosis. For patients with confirmed NAFLD, risk stratification using non-invasive fibrosis scores (such as the FIB-4 index or NAFLD Fibrosis Score) helps identify those requiring further assessment. FIB-4 cut-offs vary by age, and local pathways should be followed.

NICE diagnostic guidance DG34 recommends the Enhanced Liver Fibrosis (ELF) test for adults with NAFLD to assess the risk of advanced fibrosis. Patients with advanced fibrosis (indicated by elevated fibrosis scores, ELF results, or imaging findings), persistently abnormal liver tests despite lifestyle modification, or diagnostic uncertainty should be referred to specialist hepatology services. Regular monitoring is essential, as NAFLD can progress silently over years. Your GP will determine appropriate follow-up intervals based on individual risk factors and disease severity.

Frequently Asked Questions